Literature DB >> 28412411

Mirtazapine and ketanserin alter preference for gambling-like schedules of reinforcement in rats.

Amanda L Persons1, Stephanie E Tedford2, T Celeste3.   

Abstract

Drug and behavioral addictions have overlapping features, e.g., both manifest preference for larger, albeit costlier, reinforcement options in cost/benefit decision-making tasks. Our prior work revealed that the mixed-function serotonergic compound, mirtazapine, attenuates behaviors by rats motivated by abused drugs. To extend this work to behavioral addictions, here we determined if mirtazapine and/or ketanserin, another mixed-function serotonin-acting compound, can alter decision-making in rats that is independent of drug (or food)-motivated reward. Accordingly, we developed a novel variable-ratio task in rats wherein intracranial self-stimulation was used as the positive reinforcer. Using lever pressing for various levels of brain stimulation, the operant task provided choices between a small brain stimulation current delivered on a fixed-ratio schedule (i.e., a predictable reward) and a large brain stimulation delivered following an unpredictable number of responses (i.e., a variable-ratio schedule). This task allowed for demonstration of individualized preference and detection of shifts in motivational influences during a pharmacological treatment. Once baseline preference was established, we determined that pretreatment with mirtazapine or ketanserin significantly decreased preference for the large reinforcer presented after gambling-like schedules of reinforcement. When the rats were tested the next day without drug, preference for the unpredictable large reinforcer option was restored. These data demonstrate that mirtazapine and ketanserin can reduce preference for larger, costlier reinforcement options, and illustrate the potential for these drugs to alter behavior.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost/benefit decision-making; Gambling; Intracranial self-stimulation; Serotonin; Variable-ratio

Mesh:

Substances:

Year:  2017        PMID: 28412411      PMCID: PMC5656013          DOI: 10.1016/j.pnpbp.2017.03.027

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  63 in total

1.  Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers.

Authors:  A Bechara; S Dolan; N Denburg; A Hindes; S W Anderson; P E Nathan
Journal:  Neuropsychologia       Date:  2001       Impact factor: 3.139

2.  Serotonin 1B receptor imaging in pathological gambling.

Authors:  Marc N Potenza; Espen Walderhaug; Shannan Henry; Jean-Dominique Gallezot; Beata Planeta-Wilson; Jim Ropchan; Alexander Neumeister
Journal:  World J Biol Psychiatry       Date:  2011-09-22       Impact factor: 4.132

Review 3.  The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

Authors:  T de Boer
Journal:  Int Clin Psychopharmacol       Date:  1995-12       Impact factor: 1.659

4.  Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats.

Authors:  J McDaid; C E Tedford; A R Mackie; J E Dallimore; A L Mickiewicz; F Shen; J M Angle; T C Napier
Journal:  Drug Alcohol Depend       Date:  2006-06-08       Impact factor: 4.492

Review 5.  The role of serotonin in drug use and addiction.

Authors:  Christian P Müller; Judith R Homberg
Journal:  Behav Brain Res       Date:  2014-04-25       Impact factor: 3.332

Review 6.  Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio
Journal:  Neuropharmacology       Date:  2013-07-11       Impact factor: 5.250

7.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

8.  A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.

Authors:  E Hollander; C M DeCaria; J N Finkell; T Begaz; C M Wong; C Cartwright
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

9.  Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.

Authors:  Håkan V Wikström; Marguérite M Mensonides-Harsema; Thomas I F H Cremers; Ejner K Moltzen; Jørn Arnt
Journal:  J Med Chem       Date:  2002-07-18       Impact factor: 7.446

10.  A comparison of multiple 5-HT receptors in two tasks measuring impulsivity.

Authors:  John C Talpos; Lawrence S Wilkinson; Trevor W Robbins
Journal:  J Psychopharmacol       Date:  2005-10-04       Impact factor: 4.153

View more
  1 in total

1.  Risk-Based Decision Making: A Systematic Scoping Review of Animal Models and a Pilot Study on the Effects of Sleep Deprivation in Rats.

Authors:  Cathalijn H C Leenaars; Stevie Van der Mierden; Ruud N J M A Joosten; Marnix A Van der Weide; Mischa Schirris; Maurice Dematteis; Franck L B Meijboom; Matthijs G P Feenstra; André Bleich
Journal:  Clocks Sleep       Date:  2021-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.